Cadrenal Therapeutics, Inc. CVKD 深 沪
已收盘 04-02 16:00:00 美东时间
4.70
-0.200
-4.08%
华盛通- 最 高4.81
- 今 开4.71
- 成交量 1.37万股
- 最 低 4.54
- 昨 收 4.90
- 总市值 1098.92万
- 52周最高 17.50
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 4.21
- 委 比 -43.88%
- 总股本 233.81万
- 历史最高 101.25
- 量 比 0.31
- 振 幅 5.51%
- 历史最低 4.21
- 每 手 1
- 风险率 3.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cadrenal Therapeutics shares are trading higher. The company reported Q4 financial results.
Cadrenal Therapeutics shares are trading higher. The company reported Q4 financ...
04-01 03:35
Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over losses of $(2.80) per
03-31 22:15
美股夜盘 | 正业生物涨31.83%，Above Food Ingredients涨24.70%
正业生物涨31.83%；Above Food Ingredients涨24.70%；Faraday Future Intelligent Electric涨20.09%
03-23 10:02
美股夜盘 | 正业生物涨28.23%，Above Food Ingredients涨25.39%
正业生物涨28.23%；Above Food Ingredients涨25.39%；Faraday Future Intelligent Electric涨20.09%
03-23 09:02
美股夜盘 | Above Food Ingredients涨34.29%，正业生物涨27.14%
Linkhome Holdings Inc.涨-13.45%；Next Technology涨-13.00%；DRDGOLD Ltd. Sponsored ADR涨-11.06%
03-23 08:10
Cadrenal Therapeutics Highlights Recent Scientific Findings Demonstrating Potential Of 12-Lipoxygenase Inhibitor, CAD-1005, To Target Inflammatory Consequences Of Obesity And Type 2 Diabetes
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific findings demonstrating
03-12 20:05
Cadrenal Therapeutics Announces Data From Phase 2 Study Of CAD-1005 Shows Over 25% Absolute Reduction In Thrombotic Events; CAD-1005 Failed To Significantly Impact Platelet Recovery Rate
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results from a Phase 2 trial
02-24 21:34
Cadrenal Says New Experimental Therapy Could Change How Doctors Treat Rare Heparin Reaction
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the significant and
01-12 21:10
Cadrenal Therapeutics Acquires VLX-1005 And Related 12-Lipoxygenase Assets From Veralox Therapeutics; Terms Not Disclosed
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing,
2025-12-11 21:09
Cadrenal Therapeutics Q3 EPS $(1.31) Beats $(1.53) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.53) by 14.21 percent. This is a 39.91 percent increase over losses of $(2.18) per share
2025-11-10 22:04
